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Purpose: To evaluate the impact of presenting symptoms on survival in a contemporary 
series of patients with renal cell carcinoma (RCC).
Materials and Methods: We prospectively recorded data on the presenting symptoms, 
pathology, and RCC-specific survival of 633 consecutive RCC patients who underwent 
surgery between 2003 and 2012. 
Results: Four hundred thirty-three RCCs (68%) were incidental, 111 (18%) were asso-
ciated with local symptoms, and 89 (14%) were associated with systemic symptoms. 
Among those with incidental RCC, 317 patients (73%) were completely asymptomatic 
and 116 patients (27%) presented with symptoms not related to the tumor. During a 
median follow-up interval of 40 months (interquartile range: 39 to 69 months), 77 pa-
tients died from RCC. In univariate analyses, symptom classification was significantly 
associated with RCC-specific survival (p＜0.001). Patients with incidental RCC and 
unrelated symptoms tended to have worse prognosis than did patients who were com-
pletely asymptomatic, although this difference was not statistically significant 
(p=0.057). The symptom classification was associated with advanced TNM stages (p
＜0.001) and grade (p＜0.001).
Conclusions: This study confirms that presenting symptoms are associated with tumor 
characteristics and survival. The majority of RCCs are diagnosed incidentally in pa-
tients without any symptoms or with symptoms not related to RCC. Patients in the lat-
ter group tend to have a worse prognosis than do patients who are completely 
asymptomatic. With the increasing number of incidentally diagnosed RCCs, sub-
stratification of patients with incidental tumors may be prognostically relevant.
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INTRODUCTION
Historically, more than 90% of patients with renal cell car-
cinoma (RCC) present with symptoms and advanced stage 
disease [1–3]. With the widespread use of routine cross-sec-
tional abdominal imaging, however, the landscape of pa-
tients presenting with RCC has changed dramatically. 
Although the incidence of RCC increased initially [4], a mi-
gration toward asymptomatic and early stages was ob-
served [4,5], which ultimately led to better overall prog-
nosis [6].
About 50% of patients present with symptoms related to 
a renal tumor [3,5], which in turn leads to the initiation of 
imaging or consultation with a urologist. The presence of 
symptoms is associated with more advanced tumor stages, 
metastatic disease, and an inverse prognosis [3,7–9]. 
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Because this factor is available for all patients, it can be in-
cluded in preoperative and postoperative prognostic 
assessment. It may therefore be relevant for urologists 
when planning therapy and surveillance. There are, how-
ever, few data on the proportion of asymptomatic or in-
cidental and symptomatic cases among patients treated in 
the contemporary era of incidental renal tumors. 
Furthermore, the “incidentalness” of incidental tumors, 
i.e., the true indications and symptoms of these patients 
that led to imaging, are not well characterized. This may 
be significant for both urologists and nonurologic 
specialties.
The goals of this study were to assess the prevalence of 
presenting symptoms in a contemporary series and to eval-
uate associations with clinicopathological parameters and 
survival. Furthermore, with the identification of an in-
creasing number of incidental renal tumors, we evaluated 
the true indications for imaging. 
MATERIALS AND METHODS
1. Study design and patient selection
Data on presenting symptoms, diagnostic imaging with re-
ferring medical specialty, treatment, pathology, and 
RCC-specific survival were prospectively collected in 633 
consecutive RCC patients who were treated by partial or 
radical nephrectomy at Medical University of Vienna, 
Vienna, Austria between January 2003 and December 
2012. The study was approved by the Medical University 
of Vienna.
2. Definitions and classification
Database variables were abstracted from patient charts 
and included age, gender, preoperative Eastern Cooperat-
ive Oncology Group Performance Status (ECOG PS); T, N, 
and M stage; Fuhrman grade; histological subtype; post-
operative follow-up interval; date of death; cause of death; 
and date of recurrence. Symptoms were determined at the 
time of preoperative history and physical examination. 
Symptoms were classified according to Patard et al. [8] as 
follows: S1, asymptomatic/incidental tumor (S1a: totally 
asymptomatic, S1b: symptoms not related to renal tumor); 
S2, local symptoms; and S3, systemic symptoms. Weight 
loss was defined as an unintended decrease in weight of at 
least 5 pounds in 3 months. Paraneoplastic hypertension 
was defined as new onset of hypertension or worsening of 
preexisting hypertension [10].
Patients were staged according to the 2009 Tumor, Node, 
Metastasis criteria of the American Joint Committee on 
Cancer. Preoperative imaging included computed tomog-
raphy (CT) or magnetic resonance imaging (MRI) of the ab-
domen and pelvis and a conventional x-ray or CT of the 
chest. If patients were symptomatic for metastasis, addi-
tional imaging studies were undertaken, i.e., MRI of the liv-
er, radionuclide bone scans, and CT or MRI of the brain. 
Nuclear grade was classified according to Fuhrman and 
subtype according to the World Health Organization 
classification. Histological evaluation was performed by 
one specialized genitourinary pathologist (A.H.).
3. Statistical analysis
Categorical data are presented as numbers and pro-
portions, and continuous data as median and interquartile 
range (IQR). Group differences in categorical and con-
tinuous variables were evaluated with chi-square tests and 
Wilcoxon rank sum tests or Kruskal-Wallis tests, respec-
tively.
RCC-specific survival was calculated from the time of 
surgery to death from RCC or last follow-up, respectively. 
Cause of death was determined from death certificates, 
physician correspondence, or medical history. The 
Kaplan-Meier method was used to estimate survivor func-
tions, which were compared with log-rank tests. Univa-
riate Cox proportional hazards models were used to ad-
dress the relative impact of categorically coded system clas-
sification and other clinical and pathological variables. To 
reduce the risk of over-fitting, only variables that were sig-
nificantly associated with survival in the univariate analy-
sis were included for multivariate modeling. All statistical 
testing was two-sided and a p-value ＜0.05 was considered 
statistically significant. The statistical software STATA 
release 12 (StataCorp LP., College Station, TX, USA) was 
used for all analyses.
RESULTS
1. Patient characteristics
Six hundred thirty-three consecutive patients with spora-
dic RCC were analyzed. The patients’ median age at the 
time of surgery was 63 years (IQR, 54.3 to 72.2 years). A 
radical and partial nephrectomy was performed in 384 
(61%) and 249 patients (39%), respectively. The most com-
mon histological subtype was clear cell (70%). One hundred 
patients (16%) presented with metastatic disease. The pa-
tient and tumor characteristics are summarized in Table 
1.
2. Presenting symptoms
Four hundred and thirty-three patients (68%) were diag-
nosed with an incidental RCC (S1), of whom 317 patients 
(73%) were completely asymptomatic (S1a) and 116 pa-
tients (27%) presented with symptoms not related to the 
renal tumor (S1b). The indications for imaging in S1 cases 
are summarized in Table 2. S1a cases were most commonly 
diagnosed by routine ultrasound as part of a general health 
checkup (n=207, 33% of all cases) or by staging or follow-up 
of malignant tumors (n=74, 12% of all cases). S1b cases 
were most commonly diagnosed during workup of abdomi-
nal pain (n=38, 6% of all cases) or back pain (n=17, 3% of 
all cases). 
Patients with local symptoms (S2; n=115, 18%) pre-
sented with flank pain (n=68, 11% of all cases), painless 
gross hematuria (n=62, 10% of all cases), or a palpable tu-
mor (n=1, ＜1%). Sixteen of these patients reported both 
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TABLE 1. Characteristics and prevalence of symptoms in a series 
of 633 consecutive RCC patients
Variable Value
Age (y), median (IQR)
Gender 
    Female
    Male
ECOG PS 
    0
    ≥1
Subtype 
    Clear cell 
    Papillary 
    Chromophobe 
    Other
T stage
    pT1–T2
    pT3–T4
N stage
    pN0/Nx
    pN+
M stage
    M0
    M1
Grade
    G1–G2
    G3–G4
Symptom classification
    S1a
    S1b
    S2
    S3
  63 (54.3–72.2)
 
209 (33)
424 (67)
 
397 (63)
236 (37)
 
446 (70)
125 (20)
  53 (8)
    9 (2)
 
356 (56)
277 (44)
 
614 (97)
  19 (3)
 
539 (85)
  94 (15)
 
455 (72)
178 (28)
 
317 (50)
116 (18)
111 (18)
  89 (14)
Values are presented as number (%) unless otherwise indicated.
RCC, renal cell carcinoma; IQR, interquartile range; ECOG PS, 
Eastern Cooperative Oncology Group Performance Status.
TABLE 2. Indications for imaging that led to diagnosis of 433 
incidental renal tumors (group S1)
Group Indications for imaging No. (%)
S1a (n=317)
 
 
 
 
 
S1b (n=116)
 
 
 
 
 
 
 
General health checkup
Staging or follow‐up of cancer
Known asymptomatic renal cysts
Aortic aneurysm 
Follow‐up after solid organ transplantation
Other
Abdominal pain
Back pain
LUTS
Diarrhea/vomiting 
Testicular pain
Septicemia
Vertigo
Other
207 (65)
  74 (23)
    8 (3)
    4 (1)
    4 (1)
  20 (7)
  38 (33)
  17 (15)
  15 (13)
  10 (9)
    6 (5)
    5 (4)
    5 (4)
  20 (17)
LUTS, lower urinary tract symptoms.
flank pain and gross hematuria (3% of all cases). 
Tumors associated with systemic symptoms (S3; n=93, 
15%) were most commonly symptomatic from bone or brain 
metastasis (n=46, 7% of all cases), weight loss (n=23, 4%), 
paraneoplastic hypertension (n=17, 3%), loss of energy 
(n=10, 2%), and fever (n=4, ＜1%).
The symptom classification was significantly associated 
with preoperative ECOG PS, T stage, N stage, M stage, and 
Fuhrman grade (all p＜0.01) (Table 3). In a subgroup anal-
ysis, S1a and S1b were significantly associated with 
Fuhrman grade (p=0.025), whereas no association was ob-
served with ECOG PS, T stage, N stage, or M stage (Table 
3). The proportion of patients presenting with a pre-
operative ECOG PS of 0 was 75% in S1a and 72% in S1b 
(p=0.53) and decreased significantly to 48% in S2 and 24% 
in S3 (p＜0.001).
3. Association with RCC-specific survival 
During a median follow-up interval of 40 months (IQR, 39 
to 69 months), 77 patients died from RCC. In univariate 
analyses, ECOG PS, T stage, N stage, M stage, Fuhrman 
grade, and symptom classification were significantly asso-
ciated with RCC-specific survival (p＜0.001) (Table 4). In 
a subgroup analysis, a nonsignificant difference was noted 
between S1a and S1b (p=0.057) (Fig. 1, Table 4). In the mul-
tivariate analysis, ECOG PS, T stage, N stage, M stage, and 
grade were independent prognostic factors (Table 4).
DISCUSSION
We analyzed associations between presenting symptoms, 
pathology, and survival in a contemporary series of 633 
consecutive RCC patients. We confirmed that presenting 
symptoms are associated with pathology and RCC-specific 
survival. At our institution, about 70% of RCCs were diag-
nosed incidentally. In our cohort, a nonsignificant trend to-
ward a better prognosis for patients without any symptoms 
than for those presenting with symptoms not related to 
RCC was noted. 
It has been shown that presenting symptoms are prog-
nostically relevant in patients with RCC. This relationship 
is mainly based on the association of RCC with T stage and 
M stage, which are considered the most powerful prog-
nostic factors [8,9]. Because the evidence suggests that the 
symptom classification adds prognostic information in-
dependent of these variables [3,7], stage does not entirely 
explain the relationship between presenting symptoms 
and prognosis. 
In past decades, the proportion of incidental renal tu-
mors has increased continuously as a result of the wide-
spread use of routine cross-sectional abdominal imaging. 
The majority of these patients present either without any 
symptoms or with symptoms not related to RCC. Whereas 
only 7% to 13% of all RCCs were found incidentally in the 
1960s [11,12], this proportion may now be as high as 80% 
[13]. However, there is considerable variability in recent 
research. For example, in the studies of Tsui et al. [14] and 
Sunela et al. [5], only 15% to 19% of renal tumors were diag-
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TABLE 3. Associations of symptom classification with clinical and pathological variables of 633 patients with RCC
Variable
Symptom classification
S1a (n=317) S1b (n=116) p1 S2 (n=111) S3 (n=89) p2
ECOG PS
    0
    ≥1
T stage
    pT1–T2
    pT3–T4
N stage
    pN0/Nx
    pN+
M stage
    M0
    M1
Grade
    G1–G2
    G3–G4
Subtype
    Clear cell
    Papillary
    Chromophobe
    Other
 
239 (60)
  78 (33)
 
208 (58)
109 (39)
 
315 (51)
    2 (11)
 
303 (56)
  14 (15)
 
263 (58)
  54 (30)
 
214 (48)
  72 (58)
  28 (53)
    3 (33)
 
  84 (21)
  32 (13)
 
  70 (20)
  46 (17)
 
116 (19)
    0 (0)
 
109 (20)
    7 (7)
 
  85 (19)
  31 (17)
 
  79 (18)
  22 (18)
  12 (23)
    3 (33)
0.530
 
 
0.310
 
 
0.390
 
 
0.490
 
 
0.025
 
 
0.490
 
 
 
 
 
  53 (14)
  58 (25)
 
  52 (15)
  59 (21)
 
104 (17)
    7 (37)
 
  93 (17)
  18 (19)
 
  67 (15)
  44 (25)
 
  77 (17)
  25 (20)
    8 (15)
    1 (11)
 
21 (5)
68 (29)
 
26 (7)
63 (23)
 
79 (13)
10 (53)
 
34 (6)
55 (59)
 
40 (9)
49 (28)
 
76 (17)
  6 (5)
  5 (9)
  2 (22)
＜0.001
 
 
＜0.001
 
 
＜0.001
 
 
＜0.001
 
 
＜0.001
 
 
0.054
 
 
 
 
Values are presented as number (%).
P1 represents the p‐values of chi‐square tests for the groups S1a and S1b, p2 represents the p‐values of chi‐square tests between all 
4 groups.
RCC, renal cell carcinoma; ECOG PS, Eastern Cooperative Oncology Group Performance Status.
nosed incidentally, whereas this proportion was 58% to 
80% in other series [13,15]. Several explanations for these 
differences may exist. First, definitions and classifications 
of symptoms are somewhat general and are not 
standardized. This is specifically true for pain, which is 
multifactorial and can be related to many pathologic 
states. Differing judgment of symptoms and signs may lead 
to different symptom classification and thus in part ac-
count for the differing proportions of patients presenting 
with incidental tumors. For the current study, definitions 
from Kim et al. [10] and Patard et al. [8] were used. These 
definitions were a proposal for standardization and were 
adapted by the majority of recent studies. 
Classification of symptoms remains subjective, how-
ever, and studies on symptom prevalence are difficult to 
compare. In addition, different referral patterns from pri-
mary to tertiary care centers may contribute to differing 
proportions of incidental renal tumors. Finally, health care 
systems differ considerably between countries. Because ul-
trasound studies are frequently performed in Austria and 
many patients are screened by ultrasound during general 
health checkups or while being treated for other medical 
conditions, more tumors are discovered incidentally, al-
though ultrasound screening is not recommended in an un-
selected cohort [16,17]. 
The indications for imaging that have led to the detection 
of incidental renal tumors in contemporary series are not 
well documented. To our knowledge, only one such study 
has been published in the literature. Sand et al. [18] re-
ported that 33% of incidental renal tumors were found dur-
ing staging or follow-up of other malignant diseases. 
Another 20% of tumors were discovered on imaging con-
ducted because of signs or symptoms unrelated to RCC. The 
authors subdivided incidental renal tumors into categories 
of true and unrelated. In their study, the definitions dif-
fered considerably from the standard classification by 
Patard et al. [8]. Sand et al. [18] defined true incidental re-
nal tumors as those discovered in patients with a known 
preexisting medical condition under surveillance and un-
related as those associated with symptoms that could not 
be classified as classic symptoms from RCC. The definition 
of unrelated incidental renal tumors is almost identical to 
the S1b group in the present study. In contrast with the true 
incidental renal tumors [18], the S1a group in the present 
study also included patients who were totally asymptomatic. 
Thus, our cohort covered patients with incidental renal tu-
mors that were found during a general health checkup. In 
contrast with the case in Austria, in Norway, routine imag-
ing in healthy subjects or patients with other medical con-
ditions is rarely performed [18], which may explain this 
difference.
Our study confirms that presenting symptoms are asso-
ciated with clinicopathological variables and are prognos-
tically relevant. The symptom classification was sig-
nificantly associated with ECOG PS, T stage, N stage, M 
stage, and Fuhrman grade. Interestingly, in the subgroup 
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TABLE 4. Univariate and multivariate Cox proportional hazard regression models for RCC‐specific survival of 633 patients
Variable
Univariate Multivariate
HR 95% CI p‐value HR 95% CI p‐value
ECOG PS (≥7 vs. 0)
T stage (pT3/4 vs. pT1/2)
N stage (pN+ vs. pNx/N0)
M stage (M1 vs. M0)
Grade (G3/4 vs. G1/2)
Subtype
Symptom classification
    S1a
    S1b
    S2
    S3
5.08
5.04
10.83
22.14
5.05
0.90
 
1.00
2.13
3.70
9.84
  3.09–8.36
  2.93–8.65
  5.81–20.19
13.31–36.80
  3.16–8.06
  0.63–1.27
 
 
  0.98–4.63
  1.89–7.23
  5.27–18.36
＜0.001
＜0.001
＜0.001
＜0.001
＜0.001
0.540
 
 
0.057
＜0.001
＜0.001
1.84
2.04
2.07
10.80
1.96
‐
 
1.00
1.97
1.69
1.29
1.03–3.31
1.10–3.80
1.07–4.04
5.84–19.97
1.15–3.36
‐
 
 
0.90–4.31
0.82–3.48
0.62–2.70
0.040
0.024
0.031
＜0.001
0.013
‐
 
 
0.090
0.150
0.490
RCC, renal cell carcinoma; HR, hazard ratio; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group Performance 
Status.
FIG. 1. Kaplan-Meier specific survival according to Patard’s 
symptom classification for 633 renal cell carcinoma (RCC) 
patients: S1, asymptomatic or incidental tumor (S1a, totally 
asymptomatic; S1b, symptoms not related to renal tumor); S2, 
local symptoms; and S3, systemic symptoms. S1b patients 
tended to have worse survival than did S1a patients, but this 
difference was not statistically significant.
analysis, we showed that Fuhrman grade was significantly 
lower in asymptomatic patients than in patients present-
ing with symptoms not related to disease (S1b). This rela-
tionship could bring new insights to our understanding of 
the role of tumor grade in presenting symptoms. In the 
Kaplan-Meier analysis, we found that patients with S1b 
tumors had worse survival than did those with S1a tumors, 
although this difference was not statistically significant. 
This may indicate that symptoms judged as not being re-
lated to RCC, such as abdominal pain and back pain, may 
have been in part due to RCC. Symptom classification was 
a significant prognostic factor in the univariate but not in 
the multivariate analysis, which is possibly due to the 
strong association between symptoms and the presence of 
metastatic disease. In all, the role of incidental detection 
as an independent prognostic factor is not clear and consid-
erable disagreement exists in the literature [3,8,19–21]. 
We analyzed both symptom classification and ECOG PS. 
Although there was a very high intercorrelation between 
both variables (Table 3) that may have impacted the multi-
variate statistical analysis, the variables measure differ-
ent aspects in particular patients. Whereas the ECOG 
scale is a general measure of PS, the symptom classification 
is directly related to the disease. One may have an impaired 
PS due to concomitant comorbidity such as coronary heart 
disease or other malignancies and may be diagnosed with 
an incidental tumor (S1) [8]. Furthermore, it is possible 
that symptoms leading to the diagnosis of RCC do not im-
pact PS. Because the ECOG PS is a dynamic variable and 
we analyzed only the preoperative ECOG PS, further re-
search in this field is necessary.
Our study had several limitations. First, the study had 
a retrospective design although the data were collected 
prospectively. There was no standard for postoperative 
surveillance, which may have impacted the outcome meas-
ure and subsequent statistical evaluation. Furthermore, 
several additional prognostic factors, such as tumor ne-
crosis, were not assessed. It was a single-center series, 
which introduces selection bias. Moreover, it is likely that 
this study was underpowered to detect a significant differ-
ence in the univariate analysis between the S1a and S1b 
groups, because the numbers of included patients and 
events were low. Correspondingly, we found no significant 
difference between all symptom groups in the multivariate 
analysis, although recent data have confirmed symptoms 
to be an independent prognostic factor [7–9]. Further pro-
spective studies are necessary.
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CONCLUSIONS
This study confirms that presenting symptoms are asso-
ciated with tumor characteristics and survival. Most RCCs 
are diagnosed incidentally without any symptoms or with 
symptoms not related to RCC. Patients in the latter group 
tend to have a worse prognosis than do patients who are 
completely asymptomatic. With an increasing number of 
incidentally diagnosed RCCs, substratification of patients 
with incidental tumors may be prognostically relevant.
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